```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L1    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L2    SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10779532.str
```



chain nodes :
44 54
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14
14-15 15-16 17-18 17-21 18-19 19-20 20-21 22-23 22-26 23-24 24-25 25-26
27-28 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 37-38 37-41
38-39 39-40 40-41

```
exact/norm bonds :
7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14  14-15  15-16  17-18  17-21  18-19
 19-20  20-21  22-23  22-26  23-24  24-25  25-26  27-28  27-31  28-29  29-30  30-31
 32-33  32-36  33-34  34-35  35-36  37-38  37-41  38-39  39-40  40-41
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :


G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:Atom  44:CLASS  45:CLASS  54:CLASS  55:CLASS



L3      STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4   QUE L3 AND L1 NOT L2

=> d l4
L4 HAS NO ANSWERS
L1              SCR 1839
L2              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L3              STR
Structure diagram not available for display


Structure attributes must be viewed using STN Express query preparation.
L4              QUE  L3 AND L1 NOT L2


=> s l4 sss sam
SAMPLE SEARCH INITIATED 14:43:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   4749 TO ITERATE

 21.1% PROCESSED    1000 ITERATIONS                          19 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        90848 TO    99112
PROJECTED ANSWERS:            1235 TO     2373

L5           19 SEA SSS SAM L3 AND L1 NOT L2

=> => ....Testing the current file.... screen
```

```
ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L6    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L7    SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10779532 (a).str
```



chain nodes :
44 53
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
chain bonds :
2-53

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14
14-15  15-16  17-18  17-21  18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26
27-28  27-31  28-29  29-30  30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41
38-39  39-40  40-41
exact/norm bonds :
2-53  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14  14-15  15-16  17-18  17-21
18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26  27-28  27-31  28-29  29-30
30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41  38-39  39-40  40-41
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :


G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:Atom  44:CLASS  53:CLASS  54:CLASS



L8      STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9   QUE L8 AND L6 NOT L7

=> d 19
L9 HAS NO ANSWERS
L6              SCR 1839
L7              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L8              STR
Structure diagram not available for display


Structure attributes must be viewed using STN Express query preparation.
L9              QUE  L8 AND L6 NOT L7


=> s l9 sss sam
SAMPLE SEARCH INITIATED 14:46:34 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1242 TO ITERATE

 80.5% PROCESSED    1000 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        22726 TO    26954
PROJECTED ANSWERS:             850 TO     1832
```

```
L10           50 SEA SSS SAM L8 AND L6 NOT L7

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L11    SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L12    SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10779532 (b).str
```



chain nodes :
44 53
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
chain bonds :
2-53 4-44

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14
14-15  15-16  17-18  17-21  18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26
27-28  27-31  28-29  29-30  30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41
38-39  39-40  40-41
exact/norm bonds :
2-53  4-44  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14  14-15  15-16  17-18
17-21  18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26  27-28  27-31  28-29
29-30  30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41  38-39  39-40  40-41
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :


G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:Atom  44:CLASS  53:CLASS



L13     STRUCTURE UPLOADED

=> que L13 AND L11 NOT L12

L14  QUE L13 AND L11 NOT L12

=> d l14
L14 HAS NO ANSWERS
L11             SCR 1839
L12             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L13             STR
Structure diagram not available for display


Structure attributes must be viewed using STN Express query preparation.
L14             QUE  L13 AND L11 NOT L12


=> s l14 sss sam
SAMPLE SEARCH INITIATED 14:50:01 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    275 TO ITERATE

100.0% PROCESSED     275 ITERATIONS                          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         4506 TO     6494
PROJECTED ANSWERS:             930 TO     1948
```

```
L15          50 SEA SSS SAM L13 AND L11 NOT L12

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1839

L16   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L17   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10779532 (c).str
```



chain nodes :
52 53 54 55
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
chain bonds :
2-52 3-53 4-55 6-54

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14
14-15  15-16  17-18  17-21  18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26
27-28  27-31  28-29  29-30  30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41
38-39  39-40  40-41
exact/norm bonds :
2-52  6-54  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14  14-15  15-16  17-18
17-21  18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26  27-28  27-31  28-29
29-30  30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41  38-39  39-40  40-41
exact bonds :
3-53  4-55
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :


G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:Atom  52:CLASS  53:CLASS  54:CLASS  55:CLASS



L18     STRUCTURE UPLOADED

=> que L18 AND L16 NOT L17

L19  QUE L18 AND L16 NOT L17

=> d l19
L19 HAS NO ANSWERS
L16             SCR 1839
L17             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L18             STR
Structure diagram not available for display


Structure attributes must be viewed using STN Express query preparation.
L19             QUE  L18 AND L16 NOT L17


=> s l19 sss sam
SAMPLE SEARCH INITIATED 14:53:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    275 TO ITERATE

100.0% PROCESSED     275 ITERATIONS                                  9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          4506 TO     6494
```

```
PROJECTED ANSWERS:                9 TO      359

L20           9 SEA SSS SAM L18 AND L16 NOT L17

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L21   SCREEN CREATED

=> screen 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047

L22   SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10779532 (d).str
```



chain nodes :
52 53 55 56
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
chain bonds :
2-52 3-55 4-56 6-53

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14
14-15  15-16  17-18  17-21  18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26
27-28  27-31  28-29  29-30  30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41
38-39  39-40  40-41
exact/norm bonds :
2-52  3-55  4-56  6-53  7-8  7-11  8-9  9-10  10-11  12-13  12-16  13-14  14-15
15-16  17-18  17-21  18-19  19-20  20-21  22-23  22-26  23-24  24-25  25-26  27-28
27-31  28-29  29-30  30-31  32-33  32-36  33-34  34-35  35-36  37-38  37-41  38-39
39-40  40-41
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 7 : 12 : 17 : 22 : 27 : 32 : 37 :


G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7]

G2:H,CH3

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom  23:Atom  24:Atom  25:Atom  26:Atom  27:Atom  28:Atom
29:Atom  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom  36:Atom  37:Atom
38:Atom  39:Atom  40:Atom  41:Atom  52:CLASS  53:CLASS  55:CLASS  56:CLASS



L23     STRUCTURE UPLOADED

=> que L23 AND L21 NOT L22

L24  QUE L23 AND L21 NOT L22

=> d l24
L24 HAS NO ANSWERS
L21             SCR 1839
L22             SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L23             STR
Structure diagram not available for display


Structure attributes must be viewed using STN Express query preparation.
L24             QUE  L23 AND L21 NOT L22


=> s l24 sss sam
SAMPLE SEARCH INITIATED 14:55:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    275 TO ITERATE

100.0% PROCESSED     275 ITERATIONS                                  9 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
```

```
PROJECTED ITERATIONS:          4506 TO     6494
PROJECTED ANSWERS:                9 TO      359

L25             9 SEA SSS SAM L23 AND L21 NOT L22

=> s l24 sss ful
FULL SEARCH INITIATED 14:55:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    5700 TO ITERATE

100.0% PROCESSED     5700 ITERATIONS                          359 ANSWERS
SEARCH TIME: 00.00.01

L26           359 SEA SSS FUL L23 AND L21 NOT L22

=> => s l26
L27           19 L26

=> d l27 1-19 bib,ab,hitstr
```

L27 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:701815 CAPLUS
DN 141:185104
TI Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
IN Rudolph, Amy E.; Rocha, Ricardo; Carretero, Oscar
PA USA
SO U.S. Pat. Appl. Publ., 107 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004167197	A1	20040826	US 2004-788220	20040226
WO 2004075852	A2	20040910	WO 2004-US5609	20040226

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2004075857	A2	20040910	WO 2004-US5799	20040226

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-450529P P 20030226

AB This invention is directed generally to a method for treating a pathol. condition (particularly a cardiovascular condition (e.g., hypertension or heart failure) or a condition associated with a cardiovascular condition) using a p38-kinase inhibitor (e.g., a p38-kinase-inhibiting substituted pyrazole), and specifically a combination comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor (or "ACE inhibitor") for treating a cardiovascular condition. This invention also is directed generally to combinations comprising a p38-kinase inhibitor, and specifically to combinations comprising a p38-kinase inhibitor with an angiotensin-converting-enzyme inhibitor. This invention is further directed generally to pharmaceutical compns. comprising a p38-kinase inhibitor, and more specifically to compns. comprising the above-described combinations.

IT **740845-73-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns., combinations, and methods for treating cardiovascular conditions and other associated conditions)

RN 740845-73-2 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[1-(1,3-dihydro-5-isobenzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:287841 CAPLUS
DN 140:321349
TI Preparation of pyrazole derivatives as p38 MAP kinase inhibitors and cytokine production inhibitors
IN Hagihara, Masahiko; Shibakawa, Nobuhiko; Nishihara, Masamichi; Shirai, Toshiyuki; Shimizu, Motohisa; Hasegawa, Tohru; Tokunaga, Yasunori; Suzuki, Naoto; Wada, Yukinori
PA Ube Industries, Ltd., Japan
SO PCT Int. Appl., 276 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004029043	A1	20040408	WO 2003-JP12254	20030925

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2002-279385 A 20020925
OS MARPAT 140:321349
AB The title compds. I [R1 is optionally substituted phenyl; R2 is H, halogeno, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, or substituted amino; Q is CH or N; R3 is H, alkyl, or amino; and R4 is a group represented by the general formula Q1, etc.; R7 is H or alkyl; R8 is H, alkyl, or substituted amino; R9 is H or alkyl] are prepared Compds. of this invention in vitro showed IC50 values of 0.2 nM to 8.8 nM against p38 MAP kinase. Formulations are given.
IT **677318-82-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)
RN 677318-82-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-[3-(trifluoromethyl)-1,2,4-triazolo[4,3-b]pyridazin-6-yl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



IT **677317-98-5P 677318-04-6P 677318-06-8P**
677318-08-0P 677318-10-4P 677318-12-6P
677318-14-8P 677318-16-0P 677318-18-2P
677318-20-6P 677318-22-8P 677318-26-2P
677318-28-4P 677318-30-8P 677318-32-0P
677318-34-2P 677318-36-4P 677318-38-6P
677318-41-1P 677318-52-4P 677318-60-4P
677318-62-6P 677318-64-8P 677318-66-0P
677318-68-2P 677318-70-6P 677318-72-8P
677318-74-0P 677318-76-2P 677318-78-4P
677318-80-8P 677318-84-2P 677318-86-4P
677318-92-2P 677318-94-4P 677318-98-8P
677319-00-5P 677319-02-7P 677319-04-9P
677319-08-3P 677319-18-5P 677319-20-9P
677319-22-1P 677319-24-3P 677319-26-5P
677319-28-7P 677319-30-1P 677319-34-5P
677319-36-7P 677319-38-9P 677319-40-3P
677319-42-5P 677319-44-7P 677319-46-9P
677319-48-1P 677319-50-5P 677319-52-7P
677319-54-9P 677319-56-1P 677319-58-3P
677319-60-7P 677319-62-9P 677319-64-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

RN 677317-98-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-phenyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-04-6 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-06-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-(methylamino)-4-pyridinyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-08-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-[2-(ethylamino)-4-pyridinyl]-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-10-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-12-6 CAPLUS
CN Acetamide, N-[4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677318-14-8 CAPLUS
CN Carbamic acid, [4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 677318-16-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-5-methyl- (9CI) (CA INDEX NAME)



RN 677318-18-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4-methyl- (9CI) (CA INDEX NAME)



RN 677318-20-6 CAPLUS
CN 3(2H)-Pyridazinone, 4-amino-6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-22-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 677318-26-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-28-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-chlorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-30-8 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3,4-difluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-32-0 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-34-2 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(2-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-36-4 CAPLUS
CN 3(2H)-Pyridazinone, 6-[3-(2-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-38-6 CAPLUS
CN Acetamide, N-[4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677318-41-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[1-(1,6-dihydro-6-oxo-3-pyridazinyl)-3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677318-52-4 CAPLUS
CN 2-Pyridinamine, 4-[3-phenyl-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677318-60-4 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677318-62-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-methyl- (9CI) (CA INDEX NAME)



RN 677318-64-8 CAPLUS
CN 2-Pyridinamine, N-ethyl-4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677318-66-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 677318-68-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 677318-70-6 CAPLUS
CN Acetamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677318-72-8 CAPLUS
CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 677318-74-0 CAPLUS
CN Methanesulfonamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677318-76-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-N-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 677318-78-4 CAPLUS
CN Benzamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677318-80-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677318-84-2 CAPLUS
CN 1,2,4-Triazolo[4,3-b]pyridazin-3-amine, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 677318-86-4 CAPLUS
CN Acetamide, N-[6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-1,2,4-triazolo[4,3-b]pyridazin-3-yl]- (9CI) (CA INDEX NAME)



RN 677318-92-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677318-94-4 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677318-98-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(3,4-difluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677319-00-5 CAPLUS
CN 2-Pyridinamine, 4-[1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677319-02-7 CAPLUS
CN 2-Pyridinamine, 4-[3-(2-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677319-04-9 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-08-3 CAPLUS
CN Cyclopentanecarboxamide, N-[4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-18-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-phenyl-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-20-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-22-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-24-3 CAPLUS
CN Acetamide, N-[4-[3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-26-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 677319-28-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-4-methyl- (9CI) (CA INDEX NAME)



RN 677319-30-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-2-methyl- (9CI) (CA INDEX NAME)



RN 677319-34-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-36-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-chlorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-38-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(3,4-difluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-40-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-42-5 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(2-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-44-7 CAPLUS
CN 3(2H)-Pyridazinone, 6-[3-(2-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 677319-46-9 CAPLUS
CN Acetamide, N-[4-[3-(2-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-48-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[3-phenyl-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-50-5 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-52-7 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[3-(2-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 677319-54-9 CAPLUS
CN 2-Pyridinamine, 4-[1-(7,8-dihydro-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 677319-56-1 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 677318-04-6
CMF C18 H13 F N6 O



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 677319-58-3 CAPLUS
CN 3(2H)-Pyridazinone, 6-[3-(4-fluorophenyl)-4-[2-[(2,2,2-trifluoroethyl)amino]-4-pyridinyl]-1H-pyrazol-1-yl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 677318-10-4
CMF C20 H14 F4 N6 O



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 677319-60-7 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 677318-60-4
CMF C19 H13 F N8



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 677319-62-9 CAPLUS
CN 3(2H)-Pyridazinone, 6-[4-(2-amino-4-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-1-yl]-4,5-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 677319-20-9
CMF C18 H15 F N6 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 677319-64-1 CAPLUS
CN Acetamide, N-[4-[3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **677319-72-1P 677319-74-3P 677319-84-5P**
677320-01-3P 677320-03-5P 677320-07-9P
677320-09-1P 677320-13-7P 677320-15-9P
677320-21-7P 677320-23-9P 677320-27-3P
677320-29-5P 677320-35-3P 677320-37-5P
677320-43-3P 677320-45-5P 677320-49-9P
677320-51-3P 677320-53-5P 677320-55-7P
677320-57-9P 677320-59-1P 677320-61-5P
677320-63-7P 677320-66-0P 677320-74-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrazole derivs. as p38 MAP kinase inhibitors and cytokine production inhibitors)

RN 677319-72-1 CAPLUS

CN Carbamic acid, [4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677319-74-3 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridazinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677319-84-5 CAPLUS

CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-01-3 CAPLUS
CN Carbamic acid, [4-(3-phenyl-1H-pyrazol-4-yl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-03-5 CAPLUS
CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-phenyl-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-07-9 CAPLUS

CN Carbamic acid, [4-[3-(3-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-09-1 CAPLUS
CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-(3-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-13-7 CAPLUS
CN Carbamic acid, [4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-15-9 CAPLUS
CN Carbamic acid, [4-[3-(4-chlorophenyl)-1-(6-chloro-3-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-21-7 CAPLUS
CN Carbamic acid, [4-[3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-23-9 CAPLUS
CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-(3,4-difluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-27-3 CAPLUS
CN Carbamic acid, [4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-29-5 CAPLUS
CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-35-3 CAPLUS
CN Carbamic acid, [4-[3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-37-5 CAPLUS

CN Carbamic acid, [4-[1-(6-chloro-3-pyridinyl)-3-(2-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-43-3 CAPLUS
CN Carbamic acid, [4-[1-(6-chloro-4-methyl-3-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-45-5 CAPLUS
CN Carbamic acid, [4-[1-(6-chloro-5-methyl-3-pyridinyl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-49-9 CAPLUS

CN Carbamic acid, [4-[3-phenyl-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-51-3 CAPLUS

CN Carbamic acid, [4-[3-(3-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-53-5 CAPLUS

CN Carbamic acid, [4-[3-(4-chlorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-55-7 CAPLUS

CN Carbamic acid, [4-[3-(3,4-difluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-57-9 CAPLUS

CN Carbamic acid, [4-[1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-59-1 CAPLUS

CN Carbamic acid, [4-[3-(2-fluorophenyl)-1-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-61-5 CAPLUS
CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-(3-methyl-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-63-7 CAPLUS
CN Carbamic acid, [4-[3-(4-fluorophenyl)-1-[3-(trifluoromethyl)-1,2,4-triazolo[4,3-b]pyridazin-6-yl]-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 677320-66-0 CAPLUS
CN Carbamic acid, [4-[1-(3-amino-1,2,4-triazolo[4,3-b]pyridazin-6-yl)-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester

(9CI) (CA INDEX NAME)



RN 677320-74-0 CAPLUS
CN Carbamic acid, [4-[1-[3-(acetylamino)-1,2,4-triazolo[4,3-b]pyridazin-6-yl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:177876 CAPLUS
DN 140:235698
TI Preparation of 4-[4-(4-fluorophenyl)-isoxazol-3-yl]pyridines as immunomodulators
IN Laufer, Stefan; Striegel, Hans-Guenter; Tollmann, Karola; Albrecht, Wolfgang
PA Merckle G.m.b.H. Chem.-Pharm. Fabrik, Germany
SO Ger. Offen., 22 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 10237883	A1	20040304	DE 2002-10237883	20020819
WO 2004017968	A1	20040304	WO 2003-EP9191	20030819

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DE 2002-10237883 A 20020819
OS MARPAT 140:235698
AB Title compds. I [R1 = H, alkyl, aromatic; R2, R3 = aromatic heterocyclic (sic)] and their pharmaceutically acceptable salts were prepared For example, condensation of oxime II, e.g., prepared from 4-fluorophenylacetic acid in 2-steps, and acetic acid Et ester afforded isoxazole III. In p38 MAP kinase inhibition assays, 11-examples of compds. I exhibited IC50 values ranging from 0.4-6.75 x 10-5 M, e.g., the IC50 value of isoxazole III was 6.75 x 10-5 M. Compds. I are claimed to possess immune modulating and/or cytokine release inhibiting effects.
IT **666861-63-8P**, N-[4-[4-(4-Fluorophenyl)-3-pyridin-4-ylisoxazol-5-yl]pyridin-2-yl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of fluorophenylisoxazolpyridines as immunomodulators)
RN 666861-63-8 CAPLUS
CN Acetamide, N-[4-[4-(4-fluorophenyl)-3-(4-pyridinyl)-5-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)


N
O
N
F
AcNH
N

L27 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:874966 CAPLUS
DN 139:364918
TI Preparation of isoxazole derivatives as inhibitors of Src and other protein kinases
IN Harrington, Edmund
PA USA
SO U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003207873	A1	20031106	US 2002-119890	20020410
PRAI US 2002-119890		20020410		

OS MARPAT 139:364918
AB Isoxazole derivs. of formula I [X = alkylene, O, S, (substituted) NH, SO2, etc.; A = N, (substituted) CH; R = H, alkyl, aryl, etc.; R1 = H, alkyl, aryl, acyl, etc.; R2 = H, alkyl, CH2OH, CHO, CH2NH2, aryl, etc.] are prepared These compds. are inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. Thus, II was prepared from 3-(bis(methylthio)methylene)pentane-2,4-dione, DMF di-Me acetal and 3,5-dimethoxyphenyl guanidine. Many of the compds. tested for inhibition of Src had IC50 < 1 μM.
IT **473445-73-7P 473445-74-8P 473445-75-9P**
473445-76-0P 473445-77-1P 473445-78-2P
473445-79-3P 473445-88-4P 473445-91-9P
473445-97-5P 473445-98-6P 473446-00-3P
473446-02-5P 473446-03-6P 473446-09-2P
473446-11-6P 473446-12-7P 473446-77-4P
473446-79-6P 473446-81-0P 473446-83-2P
473447-15-3P 473447-17-5P 473447-19-7P
473447-21-1P 473447-23-3P 473447-25-5P
473447-45-9P 473447-46-0P 473447-47-1P
473447-48-2P 473447-49-3P 473447-50-6P
473447-72-2P 473448-01-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazole derivs. as inhibitors of Src, Lck, and JNK3 protein kinases)
RN 473445-73-7 CAPLUS
CN Benzonitrile, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-74-8 CAPLUS
CN Benzoic acid, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-75-9 CAPLUS
CN 2-Pyridinamine, N-(3-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473445-76-0 CAPLUS
CN 2-Pyridinamine, N-(4-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473445-77-1 CAPLUS
CN Ethanone, 1-[4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 473445-78-2 CAPLUS
CN Methanone, [4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)



RN 473445-79-3 CAPLUS
CN Benzamide, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-88-4 CAPLUS
CN 2-Pyridinamine, 4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473445-91-9 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-97-5 CAPLUS
CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473445-98-6 CAPLUS
CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473446-00-3 CAPLUS
CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 473446-02-5 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473446-03-6 CAPLUS
CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473446-09-2 CAPLUS
CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 473446-11-6 CAPLUS
CN Benzonitrile, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473446-12-7 CAPLUS
CN Benzonitrile, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473446-77-4 CAPLUS
CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 473446-79-6 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 473446-81-0 CAPLUS
CN Acetamide, N-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 473446-83-2 CAPLUS
CN 1,3-Benzenediamine, N-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 473447-15-3 CAPLUS
CN Benzenepropanoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-17-5 CAPLUS
CN Benzeneacetic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-19-7 CAPLUS
CN Benzenemethanol, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-21-1 CAPLUS
CN L-Valine, N-[3-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473447-23-3 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 473447-25-5 CAPLUS
CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473447-45-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-46-0 CAPLUS
CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-47-1 CAPLUS
CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-48-2 CAPLUS
CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-49-3 CAPLUS
CN Glycine, N-methyl-N-[[3-(methylthio)-4-[2-(phenylamino)-4-pyridinyl]-5-isoxazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 473447-50-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-5-(1-piperazinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-72-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473448-01-0 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylsulfonyl)-4-isoxazolyl]-N-phenyl-
(9CI) (CA INDEX NAME)



L27 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:590836 CAPLUS
DN 139:149624
TI Preparation of 1,4-diarylpyrazole inhibitors of src and other protein kinases
IN Young, Choon Moon
PA USA
SO U.S. Pat. Appl. Publ., 35 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003144309	A1	20030731	US 2002-146984	20020516
PRAI US 2002-146984		20020516		

OS MARPAT 139:149624
AB Title compds. I [G = XR, XAr; X = alkylidene wherein one or two non-adjacent methylene units of X are replaced by O, amino, S, CO, etc.; A = N, CR; R = H, aliphatic, etc.; Ar = (un)substituted 5-6 membered (un)saturated monocyclic ring, etc.; R1 = TnR, TnAr; n = 0-1; T = CO, CO2, COCO, etc.; R2 = H, Ar, aliphatic; R3 = R, Ar] are prepared For instance, 3-(bis(methylsulfanyl)methylene)pentane-2,4-dione (preparation given) is condensed with (pyridin-2-yl)hydrazine to give 1-[5-methyl-3-(methylsulfanyl)-1-(pyridin-2-yl)-1H-pyrazole-4-yl]ethanone. This intermediate is reacted with DMFDMA (reflux) and the resulting β-amino enone condensed with N-(3-benzyloxyphenyl)guanidine to give II. Many of the compds. have Ki ≤ 1 μM for src kinase. I are inhibitors of protein kinase, particularly inhibitors of src mammalian protein kinase involved in cell proliferation, cell death in response to extracellular stimuli.
IT **475574-61-9P 475574-62-0P 475574-81-3P**
475574-82-4P 475574-83-5P 475574-84-6P
475574-85-7P 475574-86-8P 475575-06-5P
475575-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-phenyl-4-pyrimidinyl-substituted pyrazole inhibitors of src and other protein kinases)
RN 475574-61-9 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 475574-62-0 CAPLUS
CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 475574-81-3 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-82-4 CAPLUS
CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-83-5 CAPLUS
CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-84-6 CAPLUS
CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-85-7 CAPLUS
CN Glycine, N-methyl-N-[[3-(methylthio)-1-phenyl-4-[2-(phenylamino)-4-pyridinyl]-1H-pyrazol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 475574-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-1-phenyl-5-(1-piperazinylmethyl)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-06-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-23-6 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



L27 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:150531 CAPLUS
DN 138:187765
TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi
PA G.D. Searle and Co., USA
SO U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6525059	B1	20030225	US 2000-513351	20000224
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-196623	A2	19981120	
WO 1999-US26007	A1	19991117	
US 1997-47570P	P	19970522	
US 1998-83670	A2	19980522	

OS MARPAT 138:187765
AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.
IT **216504-83-5P 216504-84-6P 216504-85-7P**
216504-86-8P 216504-87-9P 216504-88-0P
216505-92-9P 216506-33-1P 216506-39-7P
216506-40-0P 216506-41-1P 216506-42-2P
216506-64-8P 216506-65-9P 216506-66-0P
216506-67-1P 216506-72-8P 216506-73-9P
216506-82-0P 216506-83-1P 216506-85-3P
216506-87-5P 216506-93-3P 216506-95-5P

216506-96-6P 216506-98-8P 216506-99-9P
216507-01-6P 216507-03-8P 216507-04-9P
216507-06-1P 271574-67-5P 271574-81-3P
271574-82-4P 271574-83-5P 271574-84-6P
271574-85-7P 271574-86-8P 271574-87-9P
271574-88-0P 271574-89-1P 271574-90-4P
271574-91-5P 271574-93-7P 271574-96-0P
271574-97-1P 271574-98-2P 271575-03-2P
271575-04-3P 271575-05-4P 271575-07-6P
271575-09-8P 271575-10-1P 271575-11-2P
271575-12-3P 271575-21-4P 271575-22-5P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-83-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-84-6 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-87-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-88-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216505-92-9 CAPLUS
CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



●3 HCl

RN 216506-33-1 CAPLUS
CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216506-39-7 CAPLUS
CN 2(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI) (CA INDEX NAME)



RN 216506-40-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 216506-41-1 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 216506-42-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 216506-64-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216506-65-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-66-0 CAPLUS
CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-67-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-72-8 CAPLUS
CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-73-9 CAPLUS
CN 2-Pyridinamine, N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-82-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 216506-83-1 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 216506-85-3 CAPLUS
CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-87-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 216506-93-3 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-95-5 CAPLUS
CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-96-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 216506-98-8 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-99-9 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-01-6 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-03-8 CAPLUS
CN 1-Propanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-04-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271574-67-5 CAPLUS
CN Carbamic acid, [3-[[5-(4-chlorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 271574-81-3 CAPLUS
CN 1-Piperazinepropanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 271574-80-2
CMF C22 H27 F N6



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 271574-82-4 CAPLUS
CN 1,2-Propanediol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 271574-83-5 CAPLUS
CN 1,3-Propanediamine, N,N,N'-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 271574-84-6 CAPLUS
CN 1,3-Propanediamine, N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 271574-85-7 CAPLUS
CN 2-Pyridinamine, N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 271574-87-9 CAPLUS
CN 2-Pyridinamine, N-[(1-ethyl-4-piperidinyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-88-0 CAPLUS
CN 1,2-Ethanediamine, N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 271574-89-1 CAPLUS
CN 1-Pentanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-90-4 CAPLUS
CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 271574-91-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 271574-93-7 CAPLUS
CN 2-Pyridinamine, N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-96-0 CAPLUS
CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-97-1 CAPLUS
CN Benzeneethanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-98-2 CAPLUS
CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-03-2 CAPLUS
CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-04-3 CAPLUS
CN 1,4-Pentanediamine, N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 271575-05-4 CAPLUS
CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-07-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(2-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-09-8 CAPLUS

CN 1,2-Ethanediamine, N,N-diethyl-N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-10-1 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-11-2 CAPLUS
CN Benzeneethanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-12-3 CAPLUS
CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-21-4 CAPLUS
CN Cyclohexanol, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 271575-22-5 CAPLUS
CN Cyclohexanone, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:92403 CAPLUS
DN 138:137307
TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi
PA G.D. Searle and Co., USA
SO U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

Search #16

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6514977	B1	20030204	US 1998-196623	19981120
	CA 2351725	AA	20000602	CA 1999-2351725	19991117
	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	EP 1144403	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200102001	T2	20011221	TR 2001-200102001	19991117
	BR 9915420	A	20020122	BR 1999-15420	19991117
	EE 200100268	A	20021216	EE 2001-268	19991117
	NZ 512344	A	20031128	NZ 1999-512344	19991117
	AU 774262	B2	20040624	AU 2000-21454	19991117
	AT 278685	E	20041015	AT 1999-965756	19991117
	EP 1500657	A1	20050126	EP 2004-23186	19991117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 6525059	B1	20030225	US 2000-513351	20000224
	ZA 2001003882	A	20021014	ZA 2001-3882	20010514
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
	US 6423713	B1	20020723	US 2001-918481	20010731
	US 6617324	B1	20030909	US 2002-114297	20020402
	US 2004176433	A1	20040909	US 2003-374781	20030225
PRAI	US 1997-47570P	P	19970522		
	US 1998-83670	A2	19980522		
	US 1998-196623	A	19981120		
	EP 1999-965756	A3	19991117		
	WO 1999-US26007	W	19991117		
	US 2001-918481	A3	20010731		

US 2002-114297 A3 20020402

OS MARPAT 138:137307

AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TsNHNH2 to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.

IT **216504-83-5P 216504-84-6P 216504-85-7P**
216504-86-8P 216504-87-9P 216504-88-0P
216505-92-9P 216506-33-1P 216506-39-7P
216506-40-0P 216506-41-1P 216506-42-2P
216506-64-8P 216506-65-9P 216506-66-0P
216506-67-1P 216506-72-8P 216506-73-9P
216506-82-0P 216506-83-1P 216506-85-3P
216506-87-5P 216506-93-3P 216506-95-5P
216506-96-6P 216506-98-8P 216506-99-9P
216507-01-6P 216507-03-8P 216507-04-9P
216507-06-1P 271574-67-5P 271574-81-3P
271574-82-4P 271574-83-5P 271574-84-6P
271574-85-7P 271574-86-8P 271574-87-9P
271574-88-0P 271574-89-1P 271574-90-4P
271574-91-5P 271574-93-7P 271574-96-0P
271574-97-1P 271574-98-2P 271575-03-2P
271575-04-3P 271575-05-4P 271575-07-6P
271575-09-8P 271575-10-1P 271575-11-2P
271575-12-3P 271575-21-4P 271575-22-5P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-83-5 CAPLUS

CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-84-6 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-87-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-88-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216505-92-9 CAPLUS
CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 3 HCl

RN 216506-33-1 CAPLUS
CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216506-39-7 CAPLUS
CN 2(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI)

(CA INDEX NAME)



RN 216506-40-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 216506-41-1 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 216506-42-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 216506-64-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216506-65-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-66-0 CAPLUS
CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-67-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-72-8 CAPLUS
CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-73-9 CAPLUS
CN 2-Pyridinamine, N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-82-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 216506-83-1 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 216506-85-3 CAPLUS
CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-87-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 216506-93-3 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-95-5 CAPLUS
CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-96-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 216506-98-8 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-99-9 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-01-6 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-03-8 CAPLUS
CN 1-Propanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-04-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271574-67-5 CAPLUS
CN Carbamic acid, [3-[[5-(4-chlorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 271574-81-3 CAPLUS
CN 1-Piperazinepropanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 271574-80-2
CMF C22 H27 F N6



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 271574-82-4 CAPLUS
CN 1,2-Propanediol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 271574-83-5 CAPLUS
CN 1,3-Propanediamine, N,N,N'-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 271574-84-6 CAPLUS
CN 1,3-Propanediamine, N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 271574-85-7 CAPLUS
CN 2-Pyridinamine, N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 271574-87-9 CAPLUS
CN 2-Pyridinamine, N-[(1-ethyl-4-piperidinyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-88-0 CAPLUS
CN 1,2-Ethanediamine, N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 271574-89-1 CAPLUS
CN 1-Pentanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-90-4 CAPLUS
CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 271574-91-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 271574-93-7 CAPLUS
CN 2-Pyridinamine, N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-96-0 CAPLUS
CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-97-1 CAPLUS
CN Benzeneethanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-98-2 CAPLUS
CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-03-2 CAPLUS
CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-04-3 CAPLUS
CN 1,4-Pentanediamine, N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 271575-05-4 CAPLUS
CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-07-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(2-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-09-8 CAPLUS

CN 1,2-Ethanediamine, N,N-diethyl-N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-10-1 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-11-2 CAPLUS
CN Benzeneethanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-12-3 CAPLUS
CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-21-4 CAPLUS
CN Cyclohexanol, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 271575-22-5 CAPLUS
CN Cyclohexanone, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:888716 CAPLUS
DN 137:384853
TI Preparation of pyrazolyl pyridinamines and pyrimidinamines as inhibitors of Src and other protein kinases
IN Moon, Young-Choon
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092573	A2	20021121	WO 2002-US15606	20020516
	WO 2002092573	A3	20040122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1404669	A2	20040407	EP 2002-769762	20020516
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004534754	T2	20041118	JP 2002-589459	20020516
PRAI	WO 2002-US15606	W	20020516		

OS MARPAT 137:384853
AB Title compds. I [wherein G = XR or XAr; X = independently alkylidene wherein 1-2 non-adjacent methylene units are independently replaced by O, NR, S, CO, CONR, NRCO, NRCONR, SO, SO2, NRSO2, SO2NR, or NRSO2NR; A = N or CR; R = H or (un)substituted aliphatic group; or NR2 = heterocyclyl; Ar = (un)substituted 5-6 membered monocyclic ring with 0-3 heteroatoms or 8-10 membered bicyclic ring with 0-4 heteroatoms; R1 = TnR or TnAr; n = 0-1; T = CO, CO2, COCO, COCH2CO, CONR, SO2, or SO2NR; R2 = H, Ar, or (un)substituted aliphatic group; R3 = R or Ar; or pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli (no data). For example, 3-dimethylamino-1-[5-methyl-3-methylsulfanyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]propenone was coupled with N-(3-benzyloxyphenyl)guanidine in MeOH to give II (40%). I and compns. containing I are useful in the treatment and prevention of various inflammatory, autoimmune, destructive bone, proliferative, infectious, neurodegenerative, allergic, and cardiac disorders and diseases (no data).
IT **475574-61-9P**, N-(3-Pyridyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyridin-2-yl]amine **475574-62-0P**, N-(6-Methoxy-3-pyridyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyridin-2-yl]amine **475574-81-3P**, N-Phenyl-N-[4-[5-(4-morpholinylmethyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-82-4P**, N-Phenyl-N-[4-[5-((dimethylamino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-83-5P**, N-Phenyl-N-[4-[5-((diethylamino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-

pyridyl]amine **475574-84-6P**, N-Phenyl-N-[4-[5-(((methyl)(phenylmethyl)amino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-85-7P**, N-Phenyl-N-[4-[5-((((methoxycarbonyl)methyl)(methyl)amino)methyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475574-86-8P**, N-Phenyl-N-[4-[5-(1-piperazinylmethyl)-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475575-06-5P**, N-Phenyl-N-[4-[5-methyl-3-(ethylamino)-1-phenyl-1H-pyrazol-4-yl]-2-pyridyl]amine **475575-23-6P**, N-Phenyl-N-[4-[5-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyridinyl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Src protein kinase inhibitor; preparation of pyrazolyl pyridinamines and pyrimidinamine inhibitors of protein kinases using condensation, cyclization, and substitution reactions)

RN 475574-61-9 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 475574-62-0 CAPLUS
CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 475574-81-3 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-82-4 CAPLUS
CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-83-5 CAPLUS
CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-84-6 CAPLUS
CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-85-7 CAPLUS
CN Glycine, N-methyl-N-[[3-(methylthio)-1-phenyl-4-[2-(phenylamino)-4-pyridinyl]-1H-pyrazol-5-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 475574-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-1-phenyl-5-(1-piperazinylmethyl)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-06-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-23-6 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



L27 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:814127 CAPLUS
DN 137:325409
TI Preparation of isoxazole derivatives as inhibitors of Src and other protein kinases
IN Harrington, Edmund
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083668	A1	20021024	WO 2002-US11609	20020410
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2443234	AA	20021024	CA 2002-2443234	20020410
	EP 1377572	A1	20040107	EP 2002-731356	20020410
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2005500261	T2	20050106	JP 2002-581423	20020410
PRAI	US 2001-282935P	P	20010410		
	WO 2002-US11609	W	20020410		

OS MARPAT 137:325409
AB Isoxazole derivs. of formula I [X = alkylene, O, S, (substituted) NH, SO2, etc.; A = N, (substituted) CH; R = H, alkyl, aryl, etc.; R1 = H, alkyl, aryl, acyl, etc.; R2 = H, alkyl, CH2OH, CHO, CH2NH2, aryl, etc.] are prepared These compds. are inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli. Thus, II was prepared from 3-(bis(methylthio)methylene)pentane-2,4-dione, DMF di-Me acetal and 3,5-dimethoxyphenyl guanidine. Many of the compds. tested for inhibition of Src had IC50 < 1 μM.
IT **473445-73-7P 473445-74-8P 473445-75-9P**
473445-76-0P 473445-77-1P 473445-78-2P
473445-79-3P 473445-88-4P 473445-91-9P
473445-97-5P 473445-98-6P 473446-00-8P
473446-02-5P 473446-03-6P 473446-09-2P
473446-11-6P 473446-12-7P 473446-77-4P
473446-79-6P 473446-81-0P 473446-83-2P
473447-15-3P 473447-17-5P 473447-19-7P
473447-21-1P 473447-23-3P 473447-25-5P
473447-45-9P 473447-46-0P 473447-47-1P
473447-48-2P 473447-49-3P 473447-50-6P
473447-72-2P 473448-01-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoxazole derivs. as inhibitors of Src, Lck, and JNK3

protein kinases)

RN 473445-73-7 CAPLUS

CN Benzonitrile, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-74-8 CAPLUS

CN Benzoic acid, 3-[[4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-75-9 CAPLUS

CN 2-Pyridinamine, N-(3-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473445-76-0 CAPLUS

CN 2-Pyridinamine, N-(4-fluorophenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473445-77-1 CAPLUS
CN Ethanone, 1-[4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 473445-78-2 CAPLUS
CN Methanone, [4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)



RN 473445-79-3 CAPLUS
CN Benzamide, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-88-4 CAPLUS
CN 2-Pyridinamine, 4-[5-ethyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI)

(CA INDEX NAME)



RN 473445-91-9 CAPLUS
CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473445-97-5 CAPLUS
CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473445-98-6 CAPLUS
CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473446-00-3 CAPLUS
CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 473446-02-5 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473446-03-6 CAPLUS
CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473446-09-2 CAPLUS
CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 473446-11-6 CAPLUS
CN Benzonitrile, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473446-12-7 CAPLUS
CN Benzonitrile, 4-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473446-77-4 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 473446-79-6 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 473446-81-0 CAPLUS
CN Acetamide, N-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 473446-83-2 CAPLUS
CN 1,3-Benzenediamine, N-[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 473447-15-3 CAPLUS
CN Benzenepropanoic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-17-5 CAPLUS
CN Benzeneacetic acid, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-19-7 CAPLUS
CN Benzenemethanol, 3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 473447-21-1 CAPLUS
CN L-Valine, N-[3-[3-[[4-[5-methyl-3-(methylthio)-4-isoxazolyl]-2-pyridinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473447-23-3 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylthio)-4-isoxazolyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 473447-25-5 CAPLUS
CN 2-Pyridinamine, N-(6-methoxy-3-pyridinyl)-4-[5-methyl-3-(methylthio)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 473447-45-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-5-(4-morpholinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-46-0 CAPLUS
CN 2-Pyridinamine, 4-[5-[(dimethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-47-1 CAPLUS
CN 2-Pyridinamine, 4-[5-[(diethylamino)methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-48-2 CAPLUS
CN 2-Pyridinamine, 4-[5-[[methyl(phenylmethyl)amino]methyl]-3-(methylthio)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-49-3 CAPLUS
CN Glycine, N-methyl-N-[[3-(methylthio)-4-[2-(phenylamino)-4-pyridinyl]-5-isoxazolyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 473447-50-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(methylthio)-5-(1-piperazinylmethyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473447-72-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(ethylamino)-5-methyl-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 473448-01-0 CAPLUS
CN 2-Pyridinamine, 4-[5-methyl-3-(methylsulfonyl)-4-isoxazolyl]-N-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:716268 CAPLUS
DN 137:247688
TI Preparation of pyridinylpyrazoles for the treatment of COPD
IN Alonso-Alija, Cristina; Goldmann, Siegfried; Dodd, Sara; Fitzgerald, Mary; Nash, Kevin
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072571	A2	20020919	WO 2002-EP2316	20020304
	WO 2002072571	A3	20031030		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	GB 2373245	A1	20020918	GB 2001-6061	20010312
PRAI	GB 2001-6061	A	20010312		

OS MARPAT 137:247688
AB The title compds. [I; R1, R2 = H, halo, alkyl, etc.; R3 = H, halo, OH, etc.; R4 = H, halo, alkyl; or R3 and R4 together with the carbon atoms to which they are attached form a [N-alkylcarbonyl]pyrrolidin ring; R5 = alkyl; A = C, N; D = 5-10 membered aromatic ring which can contain up to 3 heteroatoms selected from the group consisting of N, O, or S], useful in medicaments, especially for the treatment of COPD, were prepared Thus, reacting 2-chloro-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]pyridine with 4-aminobenzamide afforded 18.5% II which showed IC50 of 0.13 μM against p38 map kinase.
IT **459433-62-6P 459433-63-7P 459433-64-8P**
459433-65-9P 459433-66-0P 459433-67-1P
459433-68-2P 459433-69-3P 459433-70-6P
459433-71-7P 459433-72-8P 459433-73-9P
459433-74-0P 459433-75-1P 459433-76-2P
459433-77-3P 459433-78-4P 459433-79-5P
459433-80-8P 459433-81-9P 459433-82-0P
459433-83-1P 459433-84-2P 459433-85-3P
459433-86-4P 459433-87-5P 459433-88-6P
459433-89-7P 459433-90-0P 459433-91-1P
459433-92-2P 459433-93-3P 459433-94-4P
459433-95-5P 459433-96-6P 459433-97-7P
459433-98-8P 459433-99-9P 459434-00-5P
459434-01-6P 459434-02-7P 459434-03-8P
459434-04-9P 459434-05-0P 459434-06-1P
459434-07-2P 459434-08-3P 459434-09-4P
459434-10-7P 459434-11-8P 459434-12-9P
459434-13-0P 459434-14-1P 459434-15-2P
459434-16-3P 459434-17-4P 459434-18-5P

459434-19-6P 459434-20-9P 459434-21-0P
459434-22-1P 459434-23-2P 459434-24-3P
459434-25-4P 459434-26-5P 459434-27-6P
459446-72-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinylpyrazoles for the treatment of COPD)

RN 459433-62-6 CAPLUS
CN Benzamide, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-63-7 CAPLUS
CN Benzenesulfonamide, 4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-64-8 CAPLUS
CN Phenol, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-65-9 CAPLUS
CN 2-Pyridinamine, N-(2-methoxyphenyl)-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 459433-66-0 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
RN 459433-67-1 CAPLUS
CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 459433-68-2 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 459433-69-3 CAPLUS
CN Benzenesulfonamide, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-70-6 CAPLUS
CN Acetamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459433-71-7 CAPLUS
CN Benzenesulfonamide, N-cyclopropyl-3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-72-8 CAPLUS
CN Benzenesulfonamide, N-methyl-3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-73-9 CAPLUS
CN 2-Pyridinamine, N-[4-[2-fluoro-1-(fluoromethyl)ethoxy]phenyl]-4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 459433-74-0 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-[3-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 459433-75-1 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-[4-(1H-1,2,3-triazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 459433-76-2 CAPLUS
CN Benzenesulfonamide, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-77-3 CAPLUS
CN Benzoic acid, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-78-4 CAPLUS
CN Benzenesulfonamide, N-methyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-79-5 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459433-80-8 CAPLUS
CN Benzamide, 4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-81-9 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 459433-82-0 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 459433-83-1 CAPLUS
CN Benzamide, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)



RN 459433-84-2 CAPLUS
CN Benzoic acid, 4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 459433-85-3 CAPLUS
CN Benzenesulfonamide, 4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 459433-86-4 CAPLUS
CN Benzamide, 4-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-87-5 CAPLUS
CN Benzenesulfonamide, 3-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-88-6 CAPLUS
CN Benzenesulfonamide, 4-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-89-7 CAPLUS
CN Benzamide, 4-[[4-[3-(1-methylethyl)-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-90-0 CAPLUS
CN Benzamide, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-91-1 CAPLUS
CN Benzamide, N-methyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-92-2 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459433-93-3 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459433-94-4 CAPLUS
CN Benzenesulfonamide, 3-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-95-5 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(2-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459433-96-6 CAPLUS
CN Benzamide, N,N-dimethyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-97-7 CAPLUS
CN Benzenesulfonamide, 4-[[4-[3-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-98-8 CAPLUS
CN Benzamide, 4-[[4-[3-methyl-1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459433-99-9 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-00-5 CAPLUS
CN Benzenesulfonamide, 4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-01-6 CAPLUS
CN Carbamic acid, [4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 459434-02-7 CAPLUS
CN Benzamide, 3-methyl-4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-03-8 CAPLUS
CN Pyrrolidine, 1-[[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 459434-04-9 CAPLUS
CN Benzamide, 4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-05-0 CAPLUS
CN Carbamic acid, [4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 459434-06-1 CAPLUS
CN Benzoic acid, 3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-07-2 CAPLUS
CN Benzoic acid, 3-[[3-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-08-3 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-09-4 CAPLUS
CN Benzenesulfonamide, 4-[[4-[1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-10-7 CAPLUS
CN Benzamide, 4-[[4-[1-(3-methoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-11-8 CAPLUS
CN 1,4-Benzenediamine, N-[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 459434-12-9 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[3-methyl-1-(2-pyridinyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-13-0 CAPLUS
CN Benzenesulfonamide, 4-[[4-[3-methyl-1-(2-pyridinyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-14-1 CAPLUS
CN 1,4-Benzenediamine, N-[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 459434-15-2 CAPLUS
CN Benzenesulfonamide, 4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 459434-16-3 CAPLUS
CN Benzamide, 4-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 459434-17-4 CAPLUS
CN Benzamide, 3-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-18-5 CAPLUS
CN Benzamide, 4-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 459434-19-6 CAPLUS
CN 1,4-Benzenediamine, N-[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 459434-20-9 CAPLUS
CN Benzamide, 3-[[4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 459434-21-0 CAPLUS
CN Methanesulfonamide, N-[4-[[4-[1-(7-fluoro-3-methylbenzo[b]thien-5-yl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-22-1 CAPLUS
CN Propanamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-23-2 CAPLUS
CN Ethanesulfonamide, N-(ethylsulfonyl)-N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-24-3 CAPLUS
CN Ethanesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-25-4 CAPLUS
CN Benzenesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-26-5 CAPLUS
CN 1-Propanesulfonamide, N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459434-27-6 CAPLUS
CN Acetamide, 2,2,2-trifluoro-N-[4-[[4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 459446-72-1 CAPLUS
CN Benzenesulfonamide, 3-[[4-[1-(5-benzofuranyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



L27 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:688508 CAPLUS
DN 137:232866
TI 2-Aminopyridine and 2-pyridone C-nucleosides, oligonucleotides comprising, and tests using the same oligonucleotides
IN Froehler, Brian C.; Gutierrez, Arnold J.; Matteucci, Mark D.
PA Isis Pharmaceuticals, Inc., USA
SO U.S., 18 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6447998	B1	20020910	US 1997-906378	19970805
	US 6495672	B1	20021217	US 2000-717422	20001121
	US 2003120065	A1	20030626	US 2002-171270	20020613
PRAI	US 1996-23241P	P	19960809		
	US 1997-906378	A3	19970805		
	US 2000-717422	A1	20001121		

AB The present invention provides 2-aminopyridine and 2-pyridone C-nucleosides and oligonucleotides containing the subject nucleosides. The nucleosides are useful in the preparation of the subject oligonucleotides. The oligonucleotides are useful in oligonucleotide-based diagnosis and separation through triplex binding.

IT **455944-68-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-aminopyridine and 2-pyridone C-nucleosides, oligonucleotides comprising, and triplex binding capture)

RN 455944-68-0 CAPLUS
CN D-erythro-Pentitol, 1-C-(2-amino-3,6-dimethyl-4-pyridinyl)-1,4-anhydro-2-deoxy-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:615603 CAPLUS
DN 137:169514
TI Preparation of pyrazoles as TGF-β inhibitors
IN Gellibert, Francoise Jeanne
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062787	A1	20020815	WO 2002-GB424	20020131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1363904	A1	20031126	EP 2002-710136	20020131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004521901	T2	20040722	JP 2002-563140	20020131
	US 2004097502	A1	20040520	US 2003-470862	20030731
PRAI	GB 2001-2670	A	20010202		
	GB 2001-19399	A	20010809		
	WO 2002-GB424	W	20020131		

OS MARPAT 137:169514
AB The title compds. [I; R1 = H, alkyl, CH2CONR4R5 (wherein R4 = H, alkyl; R5 = alkyl); R2 = (un)substituted (CH2)nPh, (CH2)nheterocyclyl, (CH2)nheteroaryl; R3 = H, halo, CN, etc.; n = 0-5; X, X1 = CH, N, provided that X and X1 are not both N], useful in therapy, particularly in the treatment of prophylaxis of disorders characterized by overexpression of transforming growth factor β (TGF-β), were prepared Thus reacting 4-{4-[3-(pyridin-2-yl)-1-trityl-1H-pyrazol-4-yl]-(pyridin-2-yl)amino}phenol (preparation given) with 1-(2-chloroethyl)piperidine.HCl in the presence of Cs2CO3 in Me2CO followed by trityl group removal afforded 49% I [R1, R3 = H; R2 = 4-(2-piperidinoethoxy)phenyl]. All 28 exemplified compds. I showed IC50 of 5 μM or below in TGF-β assay, and IC50 of 1 μM or below against kinase Alk5.
IT **446880-51-9P 446880-52-0P 446880-53-1P**
446880-54-2P 446880-55-3P 446880-56-4P
446880-57-5P 446880-58-6P 446880-59-7P
446880-61-1P 446880-62-2P 446880-63-3P
446880-64-4P 446880-65-5P 446880-66-6P
446880-67-7P 446880-68-8P 446880-69-9P
446880-70-2P 446880-71-3P 446880-72-4P
446880-73-5P 446880-74-6P 446880-75-7P
446880-76-8P 446880-77-9P 446880-78-0P
446880-79-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazoles as TGF-β inhibitors)

RN 446880-51-9 CAPLUS

CN 2-Pyridinamine, N-(4-chlorophenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-52-0 CAPLUS

CN 2-Pyridinamine, N-phenyl-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-53-1 CAPLUS

CN 2-Pyridinamine, N-(4-fluorophenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-54-2 CAPLUS

CN 2-Pyridinamine, N-(2-furanylmethyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-55-3 CAPLUS
CN 2-Pyridinamine, N-[3-(methylsulfonyl)phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-56-4 CAPLUS
CN Benzonitrile, 3-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 446880-57-5 CAPLUS
CN Benzonitrile, 2-methoxy-4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 446880-58-6 CAPLUS
CN 2-Pyridinamine, N-[3-[2-(1-piperidinyl)ethoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-59-7 CAPLUS
CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 446880-61-1 CAPLUS
CN 2-Pyridinamine, N-(3-chlorophenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-62-2 CAPLUS
CN 2-Pyridinamine, N-(3-methylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-63-3 CAPLUS
CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 446880-64-4 CAPLUS
CN 2-Pyridinamine, N-(3,4-dimethoxyphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-65-5 CAPLUS
CN 2-Pyridinamine, N-(4-chloro-3-methylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-66-6 CAPLUS
CN Benzonitrile, 2-chloro-5-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 446880-67-7 CAPLUS
CN Phenol, 4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 446880-68-8 CAPLUS
CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-(9CI) (CA INDEX NAME)



RN 446880-69-9 CAPLUS
CN 2-Pyridinamine, N-(4-methylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-(9CI) (CA INDEX NAME)



RN 446880-70-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 446880-71-3 CAPLUS
CN 2-Pyridinamine, N-(3,4-dimethylphenyl)-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-72-4 CAPLUS
CN 2-Pyridinamine, 4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 446880-73-5 CAPLUS
CN 2-Pyridinamine, N-[3-(1-methylethoxy)phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-74-6 CAPLUS
CN 2-Pyridinamine, N-[4-(methylsulfonyl)phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-75-7 CAPLUS
CN Benzonitrile, 2-methoxy-4-[[4-[3-(6-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 446880-76-8 CAPLUS
CN Morpholine, 4-[4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 446880-77-9 CAPLUS
CN Piperazine, 1-methyl-4-[4-[[4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 446880-78-0 CAPLUS
CN 2-Pyridinamine, N-[4-[2-(1-piperidinyl)ethoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-79-1 CAPLUS
CN 2-Pyridinamine, N-[3-[(1-methyl-1H-imidazol-2-yl)methoxy]phenyl]-4-[3-(2-pyridinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



IT **446880-85-9P 446880-86-0P 446880-87-1P**
446880-88-2P 446880-89-3P 446880-90-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles as TGF-β inhibitors)
RN 446880-85-9 CAPLUS
CN Benzoic acid, 4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 446880-86-0 CAPLUS
CN Benzoic acid, 4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 446880-87-1 CAPLUS
CN Phenol, 4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 446880-88-2 CAPLUS
CN 2-Pyridinamine, N-[4-(phenylmethoxy)phenyl]-4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-89-3 CAPLUS
CN 2-Pyridinamine, N-(4-chlorophenyl)-4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 446880-90-6 CAPLUS
CN Morpholine, 4-[4-[[4-[3-(2-pyridinyl)-1-(triphenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:591913 CAPLUS
DN 137:150215
TI Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents
IN Hatayama, Satoshi; Hayashi, Kyoko; Honma, Mitsuki; Takahashi, Ikuko
PA Banyu Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 194 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002220338	A2	20020809	JP 2001-18755	20010126
PRAI JP 2001-18755		20010126		

OS MARPAT 137:150215
AB This invention relates to the general structures (I; Ar = N-containing hetero aromatic ring, X, Z = C, etc.; Y = CO, etc.; R1-R5 = H, etc.) and their salts as Cdk4 and/or Cdk6 inhibitors. I have antiproliferative effects on cancer cells and are potential antitumor agents. Formulation examples of I capsules, tablets, and injections were given.
IT **322685-65-4 445430-71-7 445430-72-8 445430-73-9 445430-74-0 445430-77-3 445430-78-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Cdk4 and/or Cdk6 inhibitors with biaryl ureas and their salts as antitumor agents)
RN 322685-65-4 CAPLUS
CN Urea, N-[4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445430-71-7 CAPLUS
CN Urea, N-[4-(4,5-dihydro-3-methyl-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445430-72-8 CAPLUS
CN Urea, N-[4-(3-ethyl-4,5-dihydro-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445430-73-9 CAPLUS
CN Urea, N-[4-(4,5-dihydro-3-propyl-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445430-74-0 CAPLUS
CN Urea, N-[4-(4,5-dihydro-3-pentyl-5-isoxazolyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445430-77-3 CAPLUS
CN Urea, N-[4-[4,5-dihydro-3-(hydroxymethyl)-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RN 445430-78-4 CAPLUS
CN Urea, N-[4-(2-butyl-3-propyl-5-isoxazolidinyl)-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



L27 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:137207 CAPLUS
DN 134:178569
TI Preparation of as isoxazolylpyrimidines and related compounds as inhibitors of c-JUN N-terminal kinases and other protein kinases.
IN Green, Jeremy; Bemis, Guy; Grillot, Anne-Laure; Ledeboer, Mark; Salituro, Francis; Harrington, Edmund; Gao, Huai; Baker, Christopher; Cao, Jingrong; Hale, Michael
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012621	A1	20010222	WO 2000-US22445	20000811
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2381882	AA	20010222	CA 2000-2381882	20000811
	EP 1218369	A1	20020703	EP 2000-957485	20000811
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013551	A	20030617	BR 2000-13551	20000811
	JP 2003531103	T2	20031021	JP 2001-517519	20000811
	NO 2002000713	A	20020412	NO 2002-713	20020212
	US 2003149051	A1	20030807	US 2002-74177	20020212
	US 6693108	B2	20040217		
	ZA 2002001248	A	20030220	ZA 2002-1248	20020213
	US 2005026967	A1	20050203	US 2004-779532	20040213
PRAI	US 1999-148795P	P	19990813		
	US 1999-166922P	P	19991122		
	US 2000-211517P	P	20000614		
	WO 2000-US22445	W	20000811		
	US 2002-74177	A3	20020212		

OS MARPAT 134:178569
AB Title compds. [I; XYZ = NOCR2, ON:CR2, N:NNR3, OC(R2):CR2, NN(R3)CR2; R1 = H, CONH2, TnR, TnAr2; R = (substituted) aliphatyl; n = 0, 1; T = CO, CO2, CONH, SO2, SO2NH, COCH2, CH2; R2 = H, R, CH2OR, CH2OH, CHO, CH2SR, CH2SO2R, CH2NH2, CH2CN, (substituted) aryl, arylmethyl, heterocyclyl, heterocyclylmethyl, etc.; R3 = H, R, COR, CO2R, SO2R; G = R, Ar1; Ar1 = (substituted) (fused) aryl, aralkyl, heterocyclyl; Q = Q1, Q2; A = N, CR3; U = CR3, O, S, NR3; Ar2 = (substituted) (fused) aryl, heterocyclyl], were prepared Thus, 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylamine (preparation given) was refluxed with PhBr, tris(dibenzylideneacetone)dipalladium, BINAP, and NaOCMe3 were refluxed together for 16 h to give 36% 4-(5-methyl-3-phenylisoxazole-4-yl)pyrimidin-2-ylphenylamine. Several I inhibited KNK3 at <0.1 μM.
IT **326818-00-2P 326818-01-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of as isoxazolylpyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)

RN 326818-00-2 CAPLUS

CN 2-Pyridinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 326818-01-3 CAPLUS

CN 2-Pyridinamine, N-cyclohexyl-4-[3-(4-fluorophenyl)-5-(methoxymethyl)-4-isoxazolyl]- (9CI) (CA INDEX NAME)



IT **326818-49-9 326818-52-4 326818-57-9**
326818-58-0 326818-60-4 326818-62-6
326818-70-6 326818-73-9 326818-74-0
326818-98-8 326818-99-9 326819-00-5
326819-01-6 326819-32-3 326819-33-4
326819-34-5 326819-68-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of as isoxazolylpyrimidines and related compds. as inhibitors of c-JUN N-terminal kinases and other protein kinases)

RN 326818-49-9 CAPLUS

CN 2-Pyridinamine, 4-(5-ethyl-3-phenyl-4-isoxazolyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 326818-52-4 CAPLUS
CN Benzoic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]-
(9CI) (CA INDEX NAME)



RN 326818-57-9 CAPLUS
CN 2-Pyridinamine, N-(4-methoxyphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)



RN 326818-58-0 CAPLUS
CN 2-Pyridinamine, N-(3-methoxyphenyl)-4-(5-methyl-3-phenyl-4-isoxazolyl)-
(9CI) (CA INDEX NAME)



RN 326818-60-4 CAPLUS
CN Benzoic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 326818-62-6 CAPLUS
CN Benzoic acid, 4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 326818-70-6 CAPLUS
CN Ethanone, 1-[4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 326818-73-9 CAPLUS
CN Benzonitrile, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 326818-74-0 CAPLUS
CN Benzonitrile, 4-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 326818-98-8 CAPLUS
CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 326818-99-9 CAPLUS
CN 2-Pyridinamine, 4-(5-methyl-3-phenyl-4-isoxazolyl)-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)



RN 326819-00-5 CAPLUS
CN Acetamide, N-[3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 326819-01-6 CAPLUS
CN 1,3-Benzenediamine, N-[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 326819-32-3 CAPLUS
CN Benzenepropanoic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 326819-33-4 CAPLUS
CN Benzeneacetic acid, 3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 326819-34-5 CAPLUS
CN D-Valine, N-[3-[3-[[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 326819-68-5 CAPLUS
CN 4-Morpholineethanamine, N-[4-(5-methyl-3-phenyl-4-isoxazolyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:78363 CAPLUS
DN 134:147614
TI Preparation of N,N'-biarylurea derivatives as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6)
IN Hayama, Takashi; Hayashi, Kyoko; Honma, Mitsutaka; Takahashi, Ikuko
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 460 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001007411	A1	20010201	WO 2000-JP4991	20000726
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2380389	AA	20010201	CA 2000-2380389	20000726
JP 2001106673	A2	20010417	JP 2000-274175	20000726
EP 1199306	A1	20020424	EP 2000-949909	20000726
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
PRAI JP 1999-211384	A	19990726		
WO 2000-JP4991	W	20000726		

OS MARPAT 134:147614
AB N-(hetero)aryl-N'-heterocyclylurea derivs. represented by general formula (I) [wherein Ar represents a nitrogenous heterocyclic aromatic group such as (un)substituted pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyrrolyl, imidazolyl, indolyl, isoindolyl, quinolyl, isoquinolyl, benzothiazolyl, or benzoxazolyl; X and Z each represents C or N or together with R1 or R2 and/or R3 represent CH or N; Y represents CO, SO, or SO2; R1 represents hydrogen, (un)substituted lower alkyl, Y3-W2-Y4-R5, etc.; wherein R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, imidazolyl, isoxazolyl, isoquinolyl, isoindolyl, indazolyl, indolyl, indolidinyl, isothiazolyl, ethylenedioxyphenyl, oxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, quinoxalinyl, quinolyl, etc.; W2 = ingle bond, O, S, SO, SO2, N-(un)substituted NH, SO2NH, NHSO2NH, NHSO2, CONH, NHCO, NHCONH, NHCO2, etc.; Y3, Y4 = single bond, linear or branched lower alkylene; R2 and R3 each represents hydrogen, lower alkyl or alkoxy, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above), or one of R2 and R3 together with R1 and X forms cyclohexane, cyclopentane, piperidine, 3,4,5,6-tetrahydro-1,3-oxazine, tetrahydrothiopyran, pyrrolidine, tetrahydrothiofuran, oxazolidine ring, etc.; R4 and R5 represent H, halo, OH, amino, or Y3-W2-Y4-R5 (Y3, W2, Y4, R5 = same as above)] or salts thereof are prepared The compds. (e.g. II) have a remarkable proliferation-inhibitory effect on tumor cells. A Cdk4 and/or Cdk6 inhibitor for use in the therapy of malignant tumor can hence be provided. II showed IC50 of 0.061 and 0.019 μM against cyclin-D1-Cdk4 and cyclin-D2-Cdk4, resp., vs. 0.36 and 0.056 μM, resp., for (±)-flavopiridol, and inhibited the proliferation of HCT116 and MKN-1 cells with IC50 of 0.013 and 0.10 μM, resp., vs. 0.15 and 0.87

μM, resp., for (±)-flavopiridol. Pharmaceutical formulations containing I were prepared

IT **322684-16-2P 322684-17-3P 322684-18-4P**
322684-19-5P 322684-20-8P 322684-21-9P
322684-22-0P 322684-23-1P 322684-24-2P
322684-25-3P 322684-32-2P 322684-33-3P
322684-34-4P 322684-35-5P 322685-65-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(hetero)aryl-N'-heterocyclylurea derivs. as inhibitors of cyclin-dependent kinases (Cdk4 and Cdk6) and antitumor agents)

RN 322684-16-2 CAPLUS

CN Urea, N-[4-[(5S)-4,5-dihydro-3-methyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-17-3 CAPLUS

CN Urea, N-[4-[(5R)-4,5-dihydro-3-methyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-18-4 CAPLUS
CN Urea, N-[4-[(5S)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-19-5 CAPLUS
CN Urea, N-[4-[(5R)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-20-8 CAPLUS
CN Urea, N-[4-[(5S)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-21-9 CAPLUS
CN Urea, N-[4-[(5R)-3-ethyl-4,5-dihydro-5-isoxazolyl]-2-pyridinyl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-22-0 CAPLUS
CN Urea, N-[4-[(5S)-4,5-dihydro-3-propyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-23-1 CAPLUS
CN Urea, N-[4-[(5R)-4,5-dihydro-3-propyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-24-2 CAPLUS
CN Urea, N-[4-[(5S)-4,5-dihydro-3-pentyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-25-3 CAPLUS
CN Urea, N-[4-[(5R)-4,5-dihydro-3-pentyl-5-isoxazolyl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-32-2 CAPLUS
CN Urea, N-[4-[4,5-dihydro-3-(hydroxymethyl)-5-isoxazolyl]-2-pyridinyl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-33-3 CAPLUS
CN Urea, N-[4-[4,5-dihydro-3-(hydroxymethyl)-5-isoxazolyl]-2-pyridinyl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-34-4 CAPLUS
CN Urea, N-[4-(2-butyl-3-propyl-5-isoxazolidinyl)-2-pyridinyl]-N'-[(9bS)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322684-35-5 CAPLUS
CN Urea, N-[4-(2-butyl-3-propyl-5-isoxazolidinyl)-2-pyridinyl]-N'-[(9bR)-2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 322685-65-4 CAPLUS
CN Urea, N-[4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N'-(2,3,5,9b-tetrahydro-5-oxo-1H-pyrrolo[2,1-a]isoindol-9-yl)- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:368337 CAPLUS
DN 133:4656
TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 1210 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6514977	B1	20030204	US 1998-196623	19981120
	CA 2351725	AA	20000602	CA 1999-2351725	19991117
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	EP 1144403	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9915420	A	20020122	BR 1999-15420	19991117
	EE 200100268	A	20021216	EE 2001-268	19991117
	NZ 512344	A	20031128	NZ 1999-512344	19991117
	AU 774262	B2	20040624	AU 2000-21454	19991117
	AT 278685	E	20041015	AT 1999-965756	19991117
	US 6525059	B1	20030225	US 2000-513351	20000224
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
PRAI	US 1998-196623	A	19981120		
	US 1997-47570P	P	19970522		
	US 1998-83670	A2	19980522		
	WO 1999-US26007	W	19991117		

OS MARPAT 133:4656
AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared by reaction of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compound II. Data for biol. activity of I were given.
IT **216504-83-5P 216504-84-6P 216504-85-7P**
216504-86-8P 216504-87-9P 216504-88-0P
216505-92-9P 216506-33-1P 216506-39-7P

216506-40-0P 216506-41-1P 216506-42-2P
216506-64-8P 216506-65-9P 216506-66-0P
216506-67-1P 216506-72-8P 216506-73-9P
216506-82-0P 216506-83-1P 216506-85-3P
216506-87-5P 216506-93-3P 216506-95-5P
216506-96-6P 216506-98-8P 216506-99-9P
216507-01-6P 216507-03-8P 216507-04-9P
216507-06-1P 271574-67-5P 271574-81-3P
271574-82-4P 271574-83-5P 271574-84-6P
271574-85-7P 271574-86-8P 271574-87-9P
271574-88-0P 271574-89-1P 271574-90-4P
271574-91-5P 271574-93-7P 271574-96-0P
271574-97-1P 271574-98-2P 271575-03-2P
271575-04-3P 271575-05-4P 271575-07-6P
271575-09-8P 271575-10-1P 271575-11-2P
271575-12-3P 271575-21-4P 271575-22-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 216504-83-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-84-6 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-87-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)

(CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-88-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216505-92-9 CAPLUS
CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



● 3 HCl

RN 216506-33-1 CAPLUS
CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216506-39-7 CAPLUS
CN 2(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI) (CA INDEX NAME)



RN 216506-40-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 216506-41-1 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 216506-42-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 216506-64-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216506-65-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-66-0 CAPLUS
CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-67-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-

pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-72-8 CAPLUS
CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-73-9 CAPLUS
CN 2-Pyridinamine, N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-82-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-

4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 216506-83-1 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 216506-85-3 CAPLUS
CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-87-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 216506-93-3 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-95-5 CAPLUS
CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-96-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 216506-98-8 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-99-9 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-01-6 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-03-8 CAPLUS
CN 1-Propanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-04-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271574-67-5 CAPLUS
CN Carbamic acid, [3-[[5-(4-chlorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 271574-81-3 CAPLUS
CN 1-Piperazinepropanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-4-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 271574-80-2
CMF C22 H27 F N6



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 271574-82-4 CAPLUS
CN 1,2-Propanediol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 271574-83-5 CAPLUS
CN 1,3-Propanediamine, N,N,N'-triethyl-N'-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 271574-84-6 CAPLUS
CN 1,3-Propanediamine, N-[2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]ethyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)



RN 271574-85-7 CAPLUS
CN 2-Pyridinamine, N-(2-[1,4'-bipiperidin]-1'-ylethyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 271574-87-9 CAPLUS
CN 2-Pyridinamine, N-[(1-ethyl-4-piperidinyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-88-0 CAPLUS
CN 1,2-Ethanediamine, N2,N2-diethyl-N1-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 271574-89-1 CAPLUS
CN 1-Pentanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-4-methyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-90-4 CAPLUS
CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 271574-91-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 271574-93-7 CAPLUS
CN 2-Pyridinamine, N-[2-(1-ethyl-2-piperidinyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-96-0 CAPLUS
CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-97-1 CAPLUS
CN Benzeneethanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271574-98-2 CAPLUS
CN Benzenepropanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-03-2 CAPLUS
CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-04-3 CAPLUS
CN 1,4-Pentanediamine, N4-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N1,N1-diethyl- (9CI) (CA INDEX NAME)



RN 271575-05-4 CAPLUS
CN 2-Propanol, 1-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-07-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(2-methyl-1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-09-8 CAPLUS

CN 1,2-Ethanediamine, N,N-diethyl-N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-10-1 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 271575-11-2 CAPLUS
CN Benzeneethanol, β-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, (βR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 271575-12-3 CAPLUS
CN 1,4-Pentanediamine, N1,N1-diethyl-N4-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 271575-21-4 CAPLUS
CN Cyclohexanol, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 271575-22-5 CAPLUS
CN Cyclohexanone, 4-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:736693 CAPLUS
DN 131:351324
TI Preparation of 1,5-diarylpyrazoles as p38 kinase inhibitors
IN Weier, Richard M.; Collins, Paul W.; Xu, Xiangdong; Crich, Joyce Z.; Rao, Shashidhar N.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958523	A1	19991118	WO 1999-US7036	19990512
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2331878	AA	19991118	CA 1999-2331878	19990512
	AU 9938599	A1	19991129	AU 1999-38599	19990512
	EP 1077971	A1	20010228	EP 1999-921363	19990512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	US 6509361	B1	20030121	US 2001-674653	20010212
PRAI	US 1998-85494P	P	19980514		
	WO 1999-US7036	W	19990512		

OS MARPAT 131:351324
AB Title compds. [I; R = H, halo, hydrocarbyl, CO2H, etc.; R1 = H, N3, hydrocarbyl(amino), aryl, etc.; R2 = H, N3, (halo)hydrocarbyl,hydrocarbyloxycarbonyl, aryl, etc.; R3 = (un)substituted aryl; Z = N or CH] were prepared Thus, 4-propionylpyridine was condensed with Me2NCH(OMe)2 and the product cyclocondensed with 4-F-C6H4NHNH2 to give I (R = R1 = H, R2 = Me, R3 = C6H4F-4, Z = CH). Data for biol. activity of I were given.
IT **250262-86-3P 250262-87-4P 250262-88-5P**
250262-89-6P 250262-90-9P 250262-92-1P
250262-93-2P 250262-94-3P 250263-00-4P
250263-01-5P 250263-02-6P 250263-05-9P
250263-10-6P 250263-11-7P 250263-19-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,5-diarylpyrazoles as p38 kinase inhibitors)
RN 250262-86-3 CAPLUS
CN Ethanol, 2-[[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 250262-87-4 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



2 Diff

RN 250262-88-5 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 250262-89-6 CAPLUS
CN 2-Pyridinamine, N-ethyl-4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 250262-90-9 CAPLUS
CN 2-Pyridinamine, N-methyl-4-[3-methyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 250262-92-1 CAPLUS
CN Ethanol, 2-[[4-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 250262-93-2 CAPLUS
CN 2-Pyridinamine, 4-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 250262-94-3 CAPLUS
CN 2-Pyridinamine, 4-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 250263-00-4 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 250263-01-5 CAPLUS
CN 2-Pyridinamine, 4-[1-(3-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 250263-02-6 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 250263-05-9 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-1-(3-methylphenyl)-1H-pyrazol-5-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 250263-10-6 CAPLUS
CN 2-Pyridinamine, 4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 250263-11-7 CAPLUS
CN 2-Pyridinamine, 4-[1-(4-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 250263-19-5 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[1-(3-fluorophenyl)-3-methyl-1H-pyrazol-5-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:789144 CAPLUS
DN 130:38377
TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.; Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weier, Richard M.; Xu, Xiangdong
PA G.D. Searle and Co., USA; et al.
SO PCT Int. Appl., 828 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9852940	A1	19981126	WO 1998-US10436	19980522
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2291115	AA	19981126	CA 1998-2291115	19980522
	AU 9875883	A1	19981211	AU 1998-75883	19980522
	AU 754830	B2	20021128		
	ZA 9804358	A	19990524	ZA 1998-4358	19980522
	EP 1000055	A1	20000517	EP 1998-923642	19980522
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200000235	T2	20000522	TR 2000-200000235	19980522
	EE 9900527	A	20000615	EE 1999-527	19980522
	BR 9809147	A	20000801	BR 1998-9147	19980522
	JP 2002508754	T2	20020319	JP 1998-550650	19980522
	NZ 501112	A	20021025	NZ 1998-501112	19980522
	NO 9905695	A	20000121	NO 1999-5695	19991119
	MX 9910759	A	20000531	MX 1999-10759	19991122
	BG 64313	B1	20040930	BG 1999-103964	19991208
PRAI	US 1997-47570P	P	19970522		
	WO 1998-US10436	W	19980522		

OS MARPAT 130:38377
AB Title compds. [I; R1 = H, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compound II. Data for biol. activity of I were given.
IT **216504-83-5P 216504-84-6P 216504-85-7P**
216504-86-8P 216504-87-9P 216504-88-0P
216505-92-9P 216506-33-1P 216506-39-7P
216506-40-0P 216506-41-1P 216506-42-2P
216506-64-8P 216506-65-9P 216506-66-0P
216506-67-1P 216506-72-8P 216506-73-9P
216506-82-0P 216506-83-1P 216506-85-3P
216506-87-5P 216506-93-3P 216506-95-5P

216506-96-6P 216506-98-8P 216506-99-9P
216507-01-6P 216507-03-8P 216507-04-9P
216507-06-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylpyrazoles as p38 kinase inhibitors)

RN 216504-83-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-84-6 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-85-7 CAPLUS
CN 2-Pyridinamine, 4-[3-methyl-5-(2-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216504-86-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-87-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216504-88-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 216505-92-9 CAPLUS
CN 1,3-Propanediamine, N-[5-(4-fluorophenyl)-4-[2-[(phenylmethyl)amino]-4-pyridinyl]-1H-pyrazol-3-yl]-, trihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



●3 HCl

RN 216506-33-1 CAPLUS
CN 1-Butanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216506-39-7 CAPLUS
CN 2(1H)-Pyridinone, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-, hydrazone (9CI) (CA INDEX NAME)



RN 216506-40-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 216506-41-1 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 216506-42-2 CAPLUS
CN 2-Pyridinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 216506-64-8 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(2S)-2-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216506-65-9 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-66-0 CAPLUS
CN 2-Pyridinemethanamine, N-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-67-1 CAPLUS
CN 3-Pyridinemethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-72-8 CAPLUS
CN 2-Pyridinamine, N-[1-(4-fluorophenyl)ethyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-73-9 CAPLUS
CN 2-Pyridinamine, N-[(3-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-82-0 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 216506-83-1 CAPLUS
CN 1,2-Ethanediamine, N'-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 216506-85-3 CAPLUS
CN 4-Morpholineethanamine, N-[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216506-87-5 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 216506-93-3 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-95-5 CAPLUS
CN 2-Pyridinamine, N-[(4-fluorophenyl)methyl]-4-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 216506-96-6 CAPLUS
CN 2-Pyridinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-4-piperidinyl- (9CI) (CA INDEX NAME)



RN 216506-98-8 CAPLUS
CN 2-Pyridinamine, 4-[1-[2-(diethylamino)ethyl]-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 216506-99-9 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-01-6 CAPLUS
CN Ethanol, 2-[[4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-03-8 CAPLUS
CN 1-Propanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



RN 216507-04-9 CAPLUS
CN 1H-Pyrazole-1-ethanol, 3-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 216507-06-1 CAPLUS
CN 1H-Pyrazole-1-ethanol, 5-(4-fluorophenyl)-4-[2-[[(4-fluorophenyl)methyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1993:191550 CAPLUS
DN 118:191550
TI Preparation an 2-aminopyridine-3-carbonitriles as human cytomegalovirus inhibitors
IN Koeckritz, Peter; Ruhmann, Christiane; Fieblinger, Dagmar; Schroeder, Cornelia Dr; Joksch, Burkhart; Heider, Harald; Weiher, Bettina; Liebscher, Juergen
PA Berlin - Chemie AG, Germany
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 4117802	A1	19921203	DE 1991-4117802	19910530
PRAI DE 1991-4117802		19910530		

OS MARPAT 118:191550
AB Title compds. [I; R1 = H, (cyclo)alkyl, phenylalkyl, aryl, heterocyclyl, etc.; R2 = H, alkyl, phenylalkyl, aryl; R3 = H, alkyl, aryl; R1R2, R2R3 = (benzo-condensed)alkylene] were prepared by cyclization of R4R5NCR3:CR2CR1:C(CN)2 (R4, R5 = C1-4 alkyl, cycloalkyl, PhCH2, Ph, or R4R5N = pyrrolidin-1-yl, piperidino, etc,) in the presence of NH3. I (R1 = 2-thienyl, R2 = R3 = H) had IC50 of 2.5 μmol/L against human cytomegalovirus in vitro.
IT **146353-93-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as human cytomegalovirus inhibitor)
RN 146353-93-7 CAPLUS
CN 3-Pyridinecarbonitrile, 2-amino-4-(2-furanyl)- (9CI) (CA INDEX NAME)



2 Diff.

```
=> => d his

     (FILE 'HOME' ENTERED AT 14:42:44 ON 24 FEB 2005)

     FILE 'REGISTRY' ENTERED AT 14:43:05 ON 24 FEB 2005
L1               SCREEN 1839
L2               SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L3               STRUCTURE UPLOADED
L4               QUE L3 AND L1 NOT L2
L5            19 S L4 SSS SAM
L6               SCREEN 1839
L7               SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L8               STRUCTURE UPLOADED
L9               QUE L8 AND L6 NOT L7
L10           50 S L9 SSS SAM
L11              SCREEN 1839
L12              SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L13              STRUCTURE UPLOADED
L14              QUE L13 AND L11 NOT L12
L15           50 S L14 SSS SAM
L16              SCREEN 1839
L17              SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L18              STRUCTURE UPLOADED
L19              QUE L18 AND L16 NOT L17
L20            9 S L19 SSS SAM
L21              SCREEN 1839
L22              SCREEN 2016 OR  2026 OR  2039 OR  2040 OR  2045 OR  2047
L23              STRUCTURE UPLOADED
L24              QUE L23 AND L21 NOT L22
L25            9 S L24 SSS SAM
L26          359 S L24 SSS FUL

     FILE 'CAPLUS' ENTERED AT 14:56:04 ON 24 FEB 2005
L27           19 S L26

     FILE 'CAOLD' ENTERED AT 14:57:27 ON 24 FEB 2005

=> s l26
L28            0 L26

=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                                0.43     265.76

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00     -13.87

STN INTERNATIONAL LOGOFF AT 14:57:39 ON 24 FEB 2005
```